arrow
M

Malin Hultcrantz

Memorial Sloan Kettering Cancer Center
H指数:43
被引数:7,109

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model

动态风险分层在冒烟性多发性骨髓瘤中的应用:整合演变中的生物标志物与2/20/20模型

2026-09-240
OAAI
Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响:在复发/难治性多发性骨髓瘤中的作用

2026-08-070
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

2026-04-120
OAAI
Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study

SARS-CoV-2疫苗接种对意义未明的单克隆丙种球蛋白血症的影响:基于人群的iStopMM研究的结果

2026-04-110
OAAI
Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

CAR T细胞疗法后的呼吸道合胞病毒:多中心回顾性队列中的风险因素和结局

2026-02-240
PRE
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM

IMS-IMWG 2025年共识基因组分期可预测达雷木单抗为基础的四联方案对NDMM的疗效。

2026-02-190
OAAI
Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study

MPN患者转化为急性髓系白血病和骨髓增生异常综合征的风险:基于年龄和诊断时间的全国队列研究

2026-02-010
OAAI
Multiple Myeloma, Version 5.2026
2026-01-012
PRE
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

2025-11-010
OAAI
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

更正:达鲁珠单抗耐药性对复发难治性多发性骨髓瘤接受CAR T细胞治疗后临床结局的影响

2025-10-130
OA
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

daratumumab难治性对复发性难治性多发性骨髓瘤CAR T细胞治疗后临床结局的影响

2025-08-140
OAAI
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia

浆细胞异常增生患者肾移植的管理建议

2025-07-280
PRE
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma

贝兰他马福汀诱导的多发性骨髓瘤患者角膜变化的表征

2025-05-081
PRE
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

老年体弱患者接受BCMA靶向双特异性抗体治疗复发/难治性多发性骨髓瘤的结局

2025-05-060
OA